Hoth Therapeutics Faces Delisting Concerns

TL;DR

HOTH might be delisted, trading could be affected.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on November 1, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates a potential transfer of listing, with the earliest event reported as October 30, 2024. The company is incorporated in Nevada and its principal executive offices are located in New York, NY.

Why It Matters

This filing signals potential financial distress or non-compliance with exchange rules, which could significantly impact the company's stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a severe indicator of financial instability or regulatory non-compliance.

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — Registrant
• October 30, 2024 (date) — Earliest event reported
• November 1, 2024 (date) — Filing date
• Nevada (jurisdiction) — State of incorporation
• New York, New York (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value HOTH The Nasdaq Stock Mar
• $1.00 — ties to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810

Filing Documents

• ea0219197-8k_hoththera.htm (8-K) — 25KB
• 0001213900-24-093514.txt ( ) — 196KB
• hoth-20241030.xsd (EX-101.SCH) — 3KB
• hoth-20241030_lab.xml (EX-101.LAB) — 33KB
• hoth-20241030_pre.xml (EX-101.PRE) — 22KB
• ea0219197-8k_hoththera_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 30, 2024, Hoth Therapeutics, Inc. (the "Company") was notified (the "Notification Letter") by The Nasdaq Stock Market, LLC ("Nasdaq") that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common stock between September 18, 2024 and October 29, 2024, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Capital Market and, at this time, the common stock will continue to trade on The Nasdaq Capital Market under the symbol "HOTH." The Notification Letter provides that the Company has 180 calendar days, or until April 28, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company's common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by April 28, 2025, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market continued listing requirements (except for the bid price requirement) and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determin

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 1, 2024 Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer -2-

View Full Filing

View this 8-K filing on SEC EDGAR